Lack of reliability of nanotechnology in the of free plasma DNA in samples of patients with prostate cancer

2Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Background: Several studies seek biological markers that give diagnostic and degree of tumor development. The aim of this study was to validate the determination of plasma DNA using nanotechnology (Nanovue™-NV) in samples of 80 patients with prostate cancer. Methods. Blood samples of 80 patients of the Urology Ambulatory of Faculdade de Medicina do ABC with prostate cancer confirmed by anatomical-pathology criteria were analyzed. DNA extraction was performed using a GFX TM kit (Amersham Pharmacia Biotech, Inc, USA) following the adapted protocol. Plasma was subjected to centrifugation. Results: There was a big difference between the first and the second value obtained by NanoVue Only two samples had no differences between duplicates. Maximum difference between duplicates was 38 μg/mL. Average variation between 51 samples was 10.29 μg/mL, although 21 samples had differences above this average. No correlation was observed between pDNA obtained by traditional spectrophotometry and by nanotechnology. Conclusion: Determination of plasma DNA by nanotechnology was not reproducible. © 2013 Moreno et al; licensee BioMed Central Ltd.

Author supplied keywords

Cite

CITATION STYLE

APA

Moreno, R., Delgado, P. O., Coelho, P. G., Marsicano, S. R., Boas, V. A., Azzalis, L. A., … Fonseca, F. L. (2013). Lack of reliability of nanotechnology in the of free plasma DNA in samples of patients with prostate cancer. International Archives of Medicine, 6(1). https://doi.org/10.1186/1755-7682-6-2

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free